LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Ascendis Pharma A-S ADR

Închisă

SectorSănătate

211.74 2.46

Rezumat

Modificarea prețului

24h

Curent

Minim

210.85

Maxim

212.84

Indicatori cheie

By Trading Economics

Venit

-22M

-61M

Vânzări

56M

214M

Marjă de profit

-28.549

Angajați

1,017

EBITDA

-56M

-53M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+23.78% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

927M

13B

Deschiderea anterioară

209.28

Închiderea anterioară

211.74

Sentimentul știrilor

By Acuity

50%

50%

152 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 dec. 2025, 21:41 UTC

Achiziții, Fuziuni, Preluări

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 dec. 2025, 14:57 UTC

Achiziții, Fuziuni, Preluări

Accenture to Acquire Cabel Industry from Fibonacci Group

25 dec. 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dec. 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dec. 2025, 00:20 UTC

Achiziții, Fuziuni, Preluări

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dec. 2025, 22:22 UTC

Achiziții, Fuziuni, Preluări

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec. 2025, 21:26 UTC

Achiziții, Fuziuni, Preluări

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec. 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 dec. 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec. 2025, 19:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

24 dec. 2025, 19:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec. 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 dec. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 dec. 2025, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

24 dec. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 dec. 2025, 17:08 UTC

Achiziții, Fuziuni, Preluări

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec. 2025, 16:53 UTC

Achiziții, Fuziuni, Preluări

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 dec. 2025, 16:31 UTC

Market Talk
Achiziții, Fuziuni, Preluări

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 dec. 2025, 16:28 UTC

Achiziții, Fuziuni, Preluări

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 dec. 2025, 16:17 UTC

Market Talk

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 dec. 2025, 15:33 UTC

Achiziții, Fuziuni, Preluări

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 dec. 2025, 15:30 UTC

Achiziții, Fuziuni, Preluări

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec. 2025, 15:19 UTC

Achiziții, Fuziuni, Preluări

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec. 2025, 14:49 UTC

Achiziții, Fuziuni, Preluări

Mexico's Ollamani Sells Stake in Azteca Stadium

24 dec. 2025, 14:19 UTC

Market Talk

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 dec. 2025, 14:08 UTC

Achiziții, Fuziuni, Preluări

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec. 2025, 14:06 UTC

Market Talk

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 dec. 2025, 13:24 UTC

Market Talk

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 dec. 2025, 12:59 UTC

Achiziții, Fuziuni, Preluări

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec. 2025, 12:51 UTC

Achiziții, Fuziuni, Preluări

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Comparație

Modificare preț

Ascendis Pharma A-S ADR Așteptări

Obiectiv de preț

By TipRanks

23.78% sus

Prognoză pe 12 luni

Medie 263.42 USD  23.78%

Maxim 325 USD

Minim 220 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAscendis Pharma A-S ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

13 ratings

13

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

157.66 / 167.29Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

152 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat